| Activation of hepatic Nrf2 in vivo by acetaminophen in CD‐1 mice CEP Goldring, NR Kitteringham, R Elsby, LE Randle, YN Clement, ... Hepatology 39 (5), 1267-1276, 2004 | 242 | 2004 |
| Proteomic analysis of Nrf2 deficient transgenic mice reveals cellular defence and lipid metabolism as primary Nrf2-dependent pathways in the liver NR Kitteringham, A Abdullah, J Walsh, L Randle, RE Jenkins, R Sison, ... Journal of proteomics 73 (8), 1612-1631, 2010 | 205 | 2010 |
| Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials PM O'Neill, A Mukhtar, PA Stocks, LE Randle, S Hindley, SA Ward, ... Journal of medicinal chemistry 46 (23), 4933-4945, 2003 | 184 | 2003 |
| The hepatotoxic metabolite of acetaminophen directly activates the Keap1‐Nrf2 cell defense system IM Copple, CE Goldring, RE Jenkins, AJL Chia, LE Randle, JD Hayes, ... Hepatology 48 (4), 1292-1301, 2008 | 166 | 2008 |
| The generation, detection, and effects of reactive drug metabolites AV Stachulski, TA Baillie, B Kevin Park, R Scott Obach, DK Dalvie, ... Medicinal research reviews 33 (5), 985-1080, 2013 | 92 | 2013 |
| The metabolism and toxicity of furosemide in the Wistar rat and CD-1 mouse: a chemical and biochemical definition of the toxicophore DP Williams, DJ Antoine, PJ Butler, R Jones, L Randle, A Payne, ... Journal of Pharmacology and Experimental Therapeutics 322 (3), 1208-1220, 2007 | 79 | 2007 |
| Investigation of the effect of a panel of model hepatotoxins on the Nrf2-Keap1 defence response pathway in CD-1 mice LE Randle, CEP Goldring, CA Benson, PN Metcalfe, NR Kitteringham, ... Toxicology 243 (3), 249-260, 2008 | 66 | 2008 |
| α1‐Adrenoceptor antagonists prevent paracetamol‐induced hepatotoxicity in mice LE Randle, JG Sathish, NR Kitteringham, I Macdonald, DP Williams, ... British journal of pharmacology 153 (4), 820-830, 2008 | 41 | 2008 |
| Adaptation to acetaminophen exposure elicits major changes in expression and distribution of the hepatic proteome R Eakins, J Walsh, L Randle, RE Jenkins, I Schuppe-Koistinen, C Rowe, ... Scientific reports 5 (1), 16423, 2015 | 36 | 2015 |
| Development of a transactivator in hepatoma cells that allows expression of phase I, phase II, and chemical defense genes CEP Goldring, NR Kitteringham, R Jenkins, CA Lovatt, LE Randle, ... American Journal of Physiology-Cell Physiology 290 (1), C104-C115, 2006 | 35 | 2006 |
| Modelling the impact of changes in the extracellular environment on the cytosolic free NAD+/NADH ratio during cell culture RA Kelly, J Leedale, A Harrell, DA Beard, LE Randle, AE Chadwick, ... PloS one 13 (11), e0207803, 2018 | 14 | 2018 |
| Modulation of antimalarial activity at a putative bisquinoline receptor in vivo using fluorinated bisquinolines AJ Fielding, V Lukinović, PG Evans, S Alizadeh‐Shekalgourabi, RH Bisby, ... Chemistry–A European Journal 23 (28), 6811-6828, 2017 | 10 | 2017 |
| Synthesis, structural determination, and pharmacology of putative dinitroaniline antimalarials A Casino, V Lukinović, R Bhatt, LE Randle, MJ Dascombe, DBJ Fennell, ... ChemistrySelect 3 (26), 7572-7580, 2018 | 6 | 2018 |
| HPB O06 Developing a patient-derived model of cholangiocarcinoma using Precision Cut Tissue Slices (PCTS) T Gilbert, L Randle, R Diaz-Nieto, R Jones, S Fenwick, C Goldring, ... British Journal of Surgery 109 (Supplement_9), znac404. 020, 2022 | 1 | 2022 |
| Predicting physiologically-relevant oxygen concentrations in precision-cut liver slices using mathematical modelling SJ Chidlow, LE Randle, RA Kelly Plos one 17 (11), e0275788, 2022 | 1 | 2022 |
| Adrenergic modulation of chemical-induced hepatotoxicity LE Randle, DP Williams, NR Kitteringham, V Richard, BK Park, PJ O'Brien DRUG METABOLISM REVIEWS 38, 28-29, 2006 | 1 | 2006 |
| Development of doxycycline-regulatable gene expression in hepatoma cells CEP Goldring, NR Kitteringham, C Lovatt, R Jenkins, LE Randle, ... TOXICOLOGY 213 (3), 262-263, 2005 | 1 | 2005 |
| The role of metabolism in furosemide toxicity PJ Butler, LE Randle, R Jones, P Macrae, J Blagg, DA Smith, DP Williams, ... TOXICOLOGY 202 (1-2), 98-99, 2004 | 1 | 2004 |
| MOLECULAR BIOLOGY OF CHOLANGIOCARCINOMA AND ITS IMPLICATIONS FOR TARGETED THERAPY IN PATIENT MANAGEMENT TM Gilbert, L Randle, M Quinn, O McGreevy, L O’leary, R Young, ... European Journal of Surgical Oncology, 108352, 2024 | | 2024 |
| The importance of preclinical models in cholangiocarcinoma O McGreevy, M Bosakhar, T Gilbert, M Quinn, S Fenwick, H Malik, ... European Journal of Surgical Oncology, 108304, 2024 | | 2024 |
